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Background: Treatment of breast cancer with the antiestro-
gen tamoxifen is effective in approximately one half of the
patients with estrogen receptor-positive disease, but tumors
recur frequently because of the development of metastases
that are resistant to tamoxifen. We have previously shown
that mutagenesis of human estrogen-dependent ZR-75-1
breast cancer cells by insertion of a defective retrovirus ge-
nome caused the cells to become antiestrogen resistant. In
this study, we isolated and characterized the crucial gene at
the breast cancer antiestrogen resistance 1 (BCAR1) locus.
Methods/Results: Transfer of the BCAR1 locus from retro-
virus-mutated, antiestrogen-resistant cells to estrogen-
dependent ZR-75-1 cells by cell fusion conferred an anties-
trogen-resistant phenotype on the recipient cells. The
complete coding sequence of BCAR1 was isolated by use of
exon-trapping and complementary DNA (cDNA) library
screening. Sequence analysis of human BCAR1 cDNA pre-
dicted a protein of 870 amino acids that was strongly ho-
mologous to rat p130Cas-adapter protein. Genomic analysis
revealed that BCAR1 consists of seven exons and is located
at chromosome 16q23.1. BCAR1 transcripts were detected
in multiple human tissues and were similar in size to tran-
scripts produced by retrovirus-mutated ZR-75-1 cells.
Transfection of BCAR1 cDNA into ZR-75-1 cells again re-
sulted in sustained cell proliferation in the presence of anti-
estrogens, confirming that BCAR1 was the responsible gene
in the locus. Conclusions: Overexpression of the BCAR1
gene confers antiestrogen resistance on human ZR-75-1
breast cancer cells. Overexpression of BCAR1 in retrovirus-
mutated cells appears to result from activation of the gene’s
promoter. The isolation and characterization of this gene
open new avenues to elucidating mechanisms by which the
growth of human breast cancer becomes independent of es-
trogen. [J Natl Cancer Inst 2000;92:112–20]
The steroid hormone estradiol plays a pivotal role in breast
cancer initiation and cell proliferation (1,2). Estradiol and its
receptor participate in a multiprotein complex that acts as a
transcription regulator for various genes (3–6). In approximately
two thirds of all breast tumors, the estrogen receptor (ER) is
present and functionally active (7–9). The presence of the ER in
breast carcinoma cells and their responsiveness to estrogens is
clinically exploited by the administration of antagonists of es-
trogens or antiestrogens (10–12). On binding, antiestrogens in-
duce an aberrant conformation of the ER, resulting in an inactive
transcription complex (13). As a consequence, the antiestrogen-
receptor complex may bind DNA but can no longer modulate the
expression of its target genes (14). This inhibition of the estro-
gen response pathway (15) may block cellular proliferation (16–
18) and arrest tumor growth (19,20).
During the last 2 decades, antiestrogens, particularly tamoxi-
fen, have proved to be effective in the treatment of hormone-re-
sponsive breast cancer (21–23). Adjuvant treatment with tamoxifen
reduces tumor recurrence and increases survival of patients with
ER-positive breast cancer (24,25). In metastatic breast cancer,
tamoxifen leads to objective response in nearly one half of pa-
tients with ER-positive primary tumors (26). Resistance to an-
tiestrogens, however, is a serious obstacle in the management of
breast cancer. About 40% of ER-positive tumors fail to respond
to antiestrogen therapy (intrinsic resistance) (27), whereas even-
tually most, if not all, breast tumors that initially respond to
antiestrogens develop resistant metastases (acquired resistance).
The mechanisms underlying intrinsic or acquired antiestrogen
resistance of breast tumors are still poorly understood. Altered
pharmacology of the antiestrogens (19,28,29), modification of
the ER structure and function (30–32), and changes in the in-
teractions between tumor cells and their environment (paracrine
interactions) (33) have been proposed to contribute to the de-
velopment of antiestrogen resistance. In addition, genetic or epi-
genetic changes in the tumor cells that promote the development
of antiestrogen resistance have been postulated (34,35). Al-
though each of these possibilities may account for or contribute
to the resistant phenotype in individual patients, none so far has
been shown to explain antiestrogen resistance in a majority of
patients. It is likely that progression to antiestrogen resistance is
a multifactorial process.
We attempted to identify the genetic factors that may lead to
antiestrogen resistance. Therefore, we applied retroviral-
insertion mutagenesis to the human estrogen-dependent breast
cancer cell line ZR-75-1. We demonstrated that random integra-
tion of a defective murine retrovirus in the genome of ZR-75-1
cells transformed the cells from an estrogen-dependent to a
tamoxifen-resistant phenotype (36). Mapping of common inte-
gration sites and cell fusion-mediated gene transfer experiments
so far have identified three independent loci that are involved in
antiestrogen resistance (BCAR1, BCAR2, and BCAR3) (37).
Here we report the isolation and characterization of the target
gene of the BCAR1 locus and its functional involvement in
antiestrogen resistance in vitro.
MATERIALS AND METHODS
Cell Lines
The human breast carcinoma cell line ZR-75-1 and derivatives thereof were
cultured as described elsewhere (36,38). Hybrid cell lines and BCAR1-
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transfected cell lines were cultured in RPMI-1640 medium supplemented with
10% heat-inactivated bovine calf serum and 1 nM 17b-estradiol. For BCAR1-
transfected cell lines, 500 mg/mL of the neomycin analogue G418 (Life Tech-
nologies, B.V., Breda, The Netherlands) was added to the culture medium.
The tamoxifen-resistant cell line XI-13, with two copies of the defective LN
retroviral genome (36,39), one located within the BCAR1 locus, was lethally g
irradiated (40 Gy) and subsequently fused to hygromycin B-resistant ZR-75-1
(ZH3D7) cells with polyethylene glycol as described previously (37). G418 plus
hygromycin selection was performed in estradiol-containing culture medium
(37).
Molecular Biology Techniques
A human genomic cosmid library in pJB8 (40) was obtained from W. J. M.
van de Ven (University of Leuven, Leuven, Belgium) and screened by use of
standard protocols (41).
Exon trapping was performed according to the manufacturer’s instructions
(Life Technologies, Inc). In short, genomic DNA of the cosmid clones HC26 and
HC34 was partially digested with the enzyme MboI. Fragments of approximately
5–10 kilobases (kb) (average, 7.5 kb) were isolated and cloned in the exon-trap
vector pSPL3. Batches of pooled purified plasmid DNA from five clones each
were transfected into the simian kidney cell line (COS-1) (41). After transient
expression, RNA was isolated and complementary DNA (cDNA) was synthe-
sized. Following two rounds of polymerase chain reaction (PCR), the trapped
sequences were analyzed, cloned, and sequenced.
RNA was isolated from the somatic hybrid D4E5 (containing the BCAR1
locus) and cultured for 2 days with 4-hydroxy-tamoxifen by use of the CsCl–
guanidine thiocyanate procedure (41). Poly(A) RNA was selected with the use of
the PolyATtract mRNA Isolation System (Promega Corp., Madison, WI) and
converted into cDNA (Zap Express cDNA and cloning kit; Stratagene Cloning
Systems, La Jolla, CA) as recommended by the manufacturer. A cDNA library
of approximately 2 × 106 phages was created and screened. Twenty-one phage
clones hybridizing with a BCAR1 exon-trap probe were isolated and sequenced
by use of standard procedures (41). DNA and protein sequence analyses and
alignments were performed with the use of DNASIS (Hitachi Software Engi-
neering America Ltd., Brisbane, CA), Blast (www.ncbi.nlm.gov/blast), and
Clustalw (www2.ebi.ac.uk/clustalw) software. The BCAR1 sequence has been
assigned GenBank Accession No. AJ 242987.
Northern blots were prepared by use of 1% agarose–formaldehyde gels as
described previously (41). Blots were hybridized with random-primer-labeled
probes for BCAR1, the estrogen-regulated PS2 gene, and the glyceraldehyde-3-
phosphate dehydrogenase gene for loading control as described (42,43)
Mapping of the BCAR1 locus was performed on genomic DNA from a panel
of 30 somatic cell hybrids obtained from D. F. Callen (Women’s and Children’s
Hospital, Adelaide, Australia). PCR was performed with the locus-specific prim-
ers 1140 58-CCCCACATACCCAGCACA-38 and 1142 58-CCCAGCTCCTC-
CTTATTCA-38. The amplified product was verified by hybridization with the
BCAR1 locus-specific probe 18/1 (36).
Expression Constructs and Transfection of BCAR1 in
ZR-75-1 Cells
The full-length BCAR1 cDNA was inserted into the EcoRI–XhoI site of the
long terminal repeat-promoted pLXSN expression vector (39) and into a modi-
fied version of the episomal vector LZRS–IRES–Neo (LZRSpBMN–IRES) (44).
In the latter vector, the BCAR1 cDNA and the neomycin resistance gene (to
confer selectability) were separated by an IRES sequence, so that both genes
were under control of a single long terminal repeat (LTR) promoter and tran-
scribed as a polycistronic messenger.
Stable transfectants were generated with the pLXSN/BCAR1 construct by the
use of calcium phosphate precipitation (41). Transfection of ZR-75-1 cells with
the episomal LZRSpBMN–IRES/BCAR1 vector construct was performed by use
of Lipofectin reagent (Life Technologies, Inc.), according to the manufacturer’s
instructions. Transfectants were selected for neomycin resistance (500 mg of
G418/mL) in estradiol-containing medium.
Proliferation Assay
Somatic hybrid cells, BCAR1, and mock-transfected cells were grown in
culture medium supplemented with 1 nM estradiol. Cells were harvested at 80%
confluence by trypsinization. The cells (0.7 × 106) were seeded in 25-cm2 flasks,
in triplicate, and grown in the presence of either 1 mM OH-tamoxifen or 100 nM
of the pure antiestrogen ICI 182,780 (Zeneca Pharma, Ridderkerk, The Nether-
lands). After 4–6 days, the cells were again trypsinized, counted using a Coulter
Z1 cell counter (Coulter Electronics Ltd, Luton, U.K.), and reseeded in triplicate
as above. To follow the proliferation of the cells, the procedure was repeated at
several time points and for each cell line. In case of limited recovery of cells at
the end of the assay period, only two flasks were reseeded or the culture was
terminated. Proliferation was determined as the fold multiplication (mean of at
least two flasks) relative to day 0.
Drug-sensitivity tests on ZR-75-1-derived cell lines were performed in com-
plete medium containing estradiol in 96-well plates. Five thousand cells were
plated with threefold dilutions (four wells each) of the drug. After 9 days of
culture in the presence of the drug, viable cells were measured by use of the
MTT assay as described (38)
Bcar1 Protein Detection
BCAR1 and mock-transfected cells were trypsinized, rinsed with phosphate-
buffered saline, sonicated for 10 seconds, and lysed for 10 minutes at 100 °C in
1% sodium dodecyl sulfate (SDS) and 10 mM Tris–HCl (pH 7.5). The protein
concentration of the crude lysates was determined (BCA™, Protein assay re-
agent; Pierce Chemical Co., Rockford, IL). Equal amounts (3.3 mg) of protein
were used for SDS–polyacrylamide gel electrophoresis (PAGE) (8% acrylamide)
and subjected to western blot analysis as described (45). Bcar1 was visualized
with the mouse monoclonal antibody to rat p130Cas (Transductional Laborato-
ries, Lexington, KY). In addition, polyclonal antibodies raised against the N-
terminus and C-terminus of rat p130Cas (Cas N-17 and Cas C-20; Santa Cruz
Biotechnology Inc., Santa Cruz, CA) were used to identify Bcar1 in an inde-
pendent control experiment.
RESULTS
Transfer of the BCAR1 Locus by Cell Fusion
We have used retrovirus insertion-mediated mutagenesis on
the human estrogen-dependent breast cancer cell line ZR-75-1 to
generate 80 cell lines showing resistance to 4-hydroxy-
tamoxifen (36). Integration of the defective murine retrovirus
(LN) into the host cell genome could transform these cells to a
tamoxifen-resistant phenotype. With the use of integration site-
specific probes, we previously found a common integration lo-
cus for the retrovirus in a subset of this panel of cell lines. Four
independent cell clones were identified by Southern blot analy-
sis, with a viral integration in the same orientation at different
positions within a 2.2-kb genomic region (36) (see also Fig. 2,
A). We termed this locus BCAR1, for breast cancer antiestrogen
resistance 1 locus—i.e., the first BCAR locus identified.
To establish whether retroviral integration in the BCAR1
locus induces tamoxifen resistance in ZR-75-1 cells, we trans-
ferred the genomic region encompassing the BCAR1 locus from
tamoxifen-resistant cells into estrogen-dependent ZR-75-1 cells
by cell fusion. XI-13 cells carry two copies of the defective
retroviral genome, one copy of which is located within the
BCAR1 locus. On lethal g irradiation, the cells were fused to
hygromycin B-resistant ZR-75-1 cells (ZH3D7) with polyethyl-
ene glycol as described previously (37). The neomycin resis-
tance gene in the integrated retrovirus allowed the isolation of
somatic cell hybrids by dual selection with G418 plus hygro-
mycin in estradiol-containing culture medium. Twelve cell hy-
brids containing either one of the integration loci in the ZR-75-1
background were rescued and analyzed. Southern blotting analy-
sis by use of a specific probe for the neomycin resistance gene
revealed that five hybrids had retained the BCAR1 integration
locus (a 15-kb BglII fragment), whereas the remaining seven
carried the other integration locus (a 10-kb BglII fragment). Both
the virus-induced BCAR1 cell line XI-13 and the BCAR1 locus-
containing cell hybrids derived therefrom (e.g., D4E5 and
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D4E6) showed enhanced proliferation when cultured in the pres-
ence of the antiestrogen ICI 182,780 (Fig. 1, A). Hybrid cell
lines carrying the other locus, as well as the ZH3D7 recipient
cells, were growth inhibited. In the absence of antiestrogens,
BCAR1 locus-containing hybrids also demonstrated increased
proliferation compared with the control cell lines (Fig. 1, B).
Note that the proliferation of most cell lines is more efficient in
the absence of antiestrogen, which is likely because of some
residual estrogens in the serum-containing medium. In the pres-
ence of antiestrogens, the ER pathway is more effectively
blocked. The lack of the ER in XI-13 cells (36) can explain the
comparable growth levels of these cells in the presence as well
as in the absence of antiestrogens (Fig. 1). These fusion experi-
ments demonstrated unambiguously that the BCAR1 locus in-
duced antiestrogen-resistant proliferation of the somatic cell hy-
brids and that the BCAR1 phenotype is dominant.
Cloning of the BCAR1 Locus
A human cosmid library was screened with genomic probes
that have been employed to identify the BCAR1 locus (36). The
probes included a 500 base-pair (bp) ApaLI–PstI fragment
(14B2) and a 450-bp SphI fragment (18/1). Both probes reside at
the center of the viral integration site in the BCAR1 locus (Fig.
2, A). Cosmids were isolated and analyzed by restriction map-
ping, resulting in a continuous contig of approximately 80 kb
(Fig. 2, A). Unique probes derived from the 80-kb contig iden-
tified no further proviral integrations events in the 80 antiestro-
gen-resistant cell lines from our panel.
Identification of the BCAR1 Gene
Two of 10 overlapping cosmid clones covering the major part
of the BCAR1 locus—HC26 and HC34—were selected for iden-
tification of transcripts by exon trapping. A total of 31 trapped
sequences were recovered, of which 16 were related to known
genes. Eight clones corresponded to exons 2–7 of the chymo-
trypsin gene (accession No. NM_001906), and the remaining
eight appeared to be homologous to sequences of the rat
p130Cas gene (accession No. D29766) (46). Of the remaining
15 clones, two seemed to be generated because of cryptic splic-
ing events in frequently occurring alu-type repetitive sequences
in the BCAR1 locus, while the other clones did not show ho-
mology to any known sequences in available databases.
The trapped exons were hybridized to polyA messenger
RNAs (mRNAs) isolated from the antiestrogen-resistant
BCAR1 cell lines (XII-13, XI-14, and XI-13) and from the pa-
rental cell line ZR-75-1. The chymotrypsin gene sequences did
not hybridize in a northern blot analysis, indicating that this gene
is not expressed in our ZR-75-1-derived cell lines. In contrast,
exon sequences that were homologous to the rat p130Cas gene
hybridized to a single mRNA of 3.2 kb (Fig. 2, B). This tran-
script appeared to be increased in the antiestrogen-resistant cell
lines but not in the parental cell line. As shown in Fig. 2, B,
ZR-75-1 exhibits only low levels of an equally sized transcript.
The differential expression of this transcript suggested that the
rat p130Cas-homologous gene was the candidate breast cancer
antiestrogen resistance gene, BCAR1. Conclusive evidence for
its role in antiestrogen resistance required the isolation of the
BCAR1 cDNA and its functional transfer to ZR-75-1 cells by
transfection (see below).
Primary Structure of the BCAR1 Gene
A cDNA library from the antiestrogen-resistant BCAR1 cell
hybrid D4E5 was screened with p130Cas homologous se-
quences retrieved from exon trapping. Twenty-one positive
cDNA clones were identified and assembled by sequence align-
ment into a continuous cDNA of 3208 bp. The BCAR1 cDNA
encloses an open-reading frame of 2610 nucleotides. At position
122, an initiation codon is flanked by sequences matching
Kozak’s criteria (47). The open-reading frame is flanked at the
38 end by a translation termination codon (TGA) at position
2732 and a 38 untranslated sequence of 468 nucleotides that
contains multiple stop codons. A canonic polyadenylation site is
Fig 1. Antiestrogen resistance assay of somatic cell hybrids. Antiestrogen-
sensitive recipient cells (ZH3D7), antiestrogen-resistant donor cells (XI-13), and
somatic cell hybrids with (D4E5 and D4E6) and without (D1F5 and D3D0)
BCAR1 locus were cultured in triplicate in serum-containing medium with 100
nM of ICI 182,780 (panel A) or without (panel B). At the times indicated, cells
were harvested, counted, and reseeded in triplicate. The numbers of cells recov-
ered under antiestrogen at day 18 were insufficient to continue the culture of
D1F5 and only allowed for reseeding in duplicate for ZH3D7 and D3D0 (panel
A). Culture of the steadily growing XI-13 cells under antiestrogen was termi-
nated at day 27 (panel A). Indicated is the fold multiplication (mean of at least
two flasks ± standard deviation) relative to day 0. Error bars were smaller than
symbols in cases where they do not appear.
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located 14 bp in front of the start of the polyA tail in the cDNAs.
The GenBank Accession No. for the BCAR1 sequence is AJ
242987.
The open-reading frame has a coding capacity for a protein of
870 amino acid residues, with a calculated molecular mass of
approximately 93 kd. The predicted protein features a Src Ho-
mology 3 (SH3) domain in the N-terminal part and multiple
potential tyrosine phosphorylation sites (Tyr–Ala/Pro–Xxx–Pro)
in the central part of the protein (Fig. 3). The C-terminal part
encloses a proline-rich stretch (Arg–Pro–Leu–Pro–Ser–Pro–Pro)
that may interact with the SH3-binding site of the Src protein
(48). Sequence alignment of Bcar1 revealed extensive homology
(91%) with rat and mouse p130Cas protein (Fig. 3).
When hybridized with BCAR1 cDNA probes, RNA prepara-
tions of BCAR1 cell lines displayed a single transcript of ap-
proximately 3.2 kb (Fig. 2, B). The size of the mRNA is in
agreement with that of the cDNA, suggesting that the cDNA
represents the full-length transcript. Northern blots of mRNAs
derived from a panel of multiple human tissues hybridized to the
BCAR1 cDNA probe showed that the BCAR1 transcript is
widely expressed (Fig. 4). The 3.2-kb mRNA was present in all
tissues tested, being most abundant in testis and with only a low
representation in liver, thymus, and peripheral blood leukocytes.
Additionally, in vitro transcription and translation of the
BCAR1 cDNA demonstrated that the cDNA encodes a protein
with an apparent molecular mass of approximately 116 kd on
SDS–PAGE. The discrepancy in observed and calculated (93-
kd) molecular mass is probably because of folding of the mol-
ecule, causing aberrant gel mobility. Both rat p130Cas and the
Bcar1 protein exhibit the same size. As expected, a monoclonal
Fig. 2. A) Physical map of the human BCAR1 locus. At the top, the relative
position of the BCAR1 gene and part of the chymotrypsin gene (CTRB) is shown
(black bars) at a scale in kilobases (kb). The positions are shown of five
representative overlapping cosmid clones, forming a continuous contig of 80 kb.
At the bottom is an exploded view of the 2.2-kb integration region. Arrows
indicate integration sites in various tamoxifen-resistant BCAR1 cell lines. Note
that each arrow represents an integration event in an individual BCAR1 cell
line. The BCAR1 locus-specific probes 18/1 and 14B2 are shown as shaded
boxes. (Sp 4 SphI, S 4 SstI, P 4 PstI, A 4 ApaLI, E 4 EcoRI, K 4 KpnI,
and B 4 BamHI). B) Schematic representation of the BCAR1 gene (not to
scale). Shown are the relative positions of the 58 viral LTR, a putative CpG
island, and the complete BCAR1 gene consisting of seven exons. Underneath,
the BCAR1 complementary DNA is drawn encompassing an 870 amino acid
open-reading frame with an SH3 domain in the N-terminal part. The insert on
the left presents a northern blot containing approximately 3 mg of polyA mes-
senger RNA of three representative BCAR1 antiestrogen-resistant cell clones
raised by retroviral insertion mutagenesis (XII-13, XI-14, and XI-13) and ZR-
75-1 cells. The blot was hybridized with trapped sequences homologous to rat
p130Cas (top panel) or with glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) probe to control for loading (bottom panel). Blots were washed until
0.3 × standard saline citrate at 65 °C for 30 minutes. LTR 4 long terminal
repeats; bp 4 base pair.
Fig. 3. Bcar1 alignment with p130Cas. A Blast (www.ncbi.nlm.gov/blast) search
with BCAR1 complementary DNA sequences in available databases demon-
strated homology to rat and murine p130Cas sequences. An alignment is shown
of the predicted protein sequences of human Bcar1 with rat and mouse p130Cas.
A single gap of four amino acid residues has been introduced by the Clustalw
program (www2.ebi.ac.uk/clustalw) for optimal alignment. An SH3 homology
domain (boxed), a proline-rich sequence region (bold and underlined), and
multiple potential tyrosine phosphorylation sites (shaded) are indicated. The
BCAR1 sequence has been assigned GenBank accession No. AJ 242987.
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antibody directed against rat p130Cas identified the BCAR1
gene product (Fig. 5, A) as well as polyclonal antibodies that are
directed against either the N-terminus or the C-terminus of the
rat p130Cas (data not shown).
Genomic Organization of BCAR1
The genomic organization of the BCAR1 gene was delineated
by use of the BCAR1 cDNA as a template. Restriction mapping
and partial sequencing of cosmid clones HC26 and HC3 re-
vealed that the transcribed region of the BCAR1 gene consists of
seven exons (I–VII) spanning approximately 25 kb of genomic
DNA (Fig 2, B). The size of the exons varies from 76 to 1101 bp,
and the size of the introns varies from 182 bp to approximately
8.5 kb. Sequencing through the exon–intron boundaries demon-
strated that all splice junctions conform to the GT/AG rule for
exon–intron junctions. Southern blot analysis showed that all
restriction fragments from the cosmid clones that hybridized to
BCAR1 cDNA were also present in genomic DNA. More im-
portant, the coding sequence of the BCAR1 gene was found to
be identical to that of the cDNA, excluding cloning artifacts.
Exon 1 of BCAR1 contained the first 12 bp of the coding
sequence. It is of interest that this position of the exon–intron
boundary exactly matched the position where alternative splic-
ing has been observed in rat as well as mouse p130Cas (46,49).
Exons 2–6 all mapped within the coding sequence, and exon 7
contained the last 509 coding nucleotides and the complete 38
nontranslated region. The 58 flanking region of the BCAR1 gene
had a high G + C content (80%) and lacks suppression of CpG
dinucleotides, which is characteristic for CpG islands. Such a
configuration, which is often found for housekeeping genes, is
consistent with the ubiquitous expression of the BCAR1 gene
(Fig. 4).
In situ hybridization with the complete cosmid HC26 sug-
gested that the BCAR1 gene was located at human chromosome
16q22–23 (Van Agthoven T: personal communication). Primers
specific for the integration region were used to analyze a panel
of radiation hybrids containing fragments of human chromo-
some 16. PCR analysis on genomic DNA derived from these
Fig. 5. Characterization of BCAR1/p130Cas trans-
fectants. A) Left panel—Growth curves of a repre-
sentative selection of BCAR1-transfected cell lines
grown in the presence of antiestrogen. Three flasks
of each LXSN/BCAR1/p130Cas-transfected cell line
(4A12, B4, B6, and C4), the somatic cell hybrid
(D4E6), and vector-only control cell lines (C2, C6,
D2, and D4) were cultured in the presence of OH–
tamoxifen (OH–Tam) (1 mM). At indicated time
points, three flasks were harvested, processed for
cell counting, and reseeded. The number of cells
recovered for C2 only allowed for reseeding in du-
plicate for the last time point. Indicated is the fold
multiplication (mean of at least two flasks ± standard
deviation) relative to day 0 (see Fig. 1). Right
panel—A typical western blot of cell lysates (3.3 mg
protein) separated on sodium dodecyl sulfate–
polyacrylamide gel electrophoresis (SDS–PAGE)
(8%), transferred to nitrocellulose filters, and visu-
alized with mouse monoclonal antibody to rat
p130Cas. The blot contained cell lysates isolated
from these cell lines at day 12/13. An arrow indi-
cates the direction of migration in SDS–PAGE gels,
and an arrowhead marks the position of Bcar1/
p130Cas. Similar expression levels were observed
on day 0 and on day 5/6. B) RNA was prepared from
the indicated cell lines after culture in bovine calf
serum-containing medium (BCS) supplemented with
1 nM of estradiol (E2) or 1 mM of OH–Tam for 5
days. Approximately 5 mg of RNA was blotted and
hybridized with probes for glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) and PS2. Blots
were washed until 0.3 × standard saline citrate at
65 °C for 30 minutes.
Fig. 4. Expression of BCAR1 in various human tissues. Commercially available
northern blots containing polyA messenger RNA (2 mg) of multiple human
tissues (MTN blots; Clontech Laboratories, Inc, Palo Alto, CA) and checked for
loading by the supplier were hybridized with a labeled BCAR1 total comple-
mentary DNA, washed until 0.3 × standard saline citrate at 65 °C for 30 minutes,
and exposed to an x-ray film for 4 days at −70 °C with an intensifying screen.
Size markers are indicated.
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hybrid cell lines determined the position of the BCAR1 locus to
16q23.1. Hybrids lacking the region 16q23.2 to telomere (e.g.,
CY145) gave no BCAR1-specific product, whereas hybrids that
retained the 16q23.1 region (e.g., CY116 and CY117) gave spe-
cific products (50). Evidence for this position of the BCAR1
gene was further supported by the concurrent trapping of exons
of the chymotrypsin gene that had been assigned to chromosome
16q23.1 (50). Hybridization with chymotrypsin gene probes on
the BCAR1 cosmid clones confirmed the position of the
chymotrypsin gene 4–5 kb downstream of the BCAR1 gene
(Fig. 2, A).
Considering the vast homology of the BCAR1 cDNA with rat
and murine p130Cas sequences and the strict conservation of the
first exon–intron boundary, we postulate that the BCAR1 gene is
the human p130Cas homologue, and we will further refer to this
gene as BCAR1/p130Cas.
Transfection of BCAR1/p130Cas cDNA and Estrogen
Independence in ZR-75-1 Cells
To demonstrate that Bcar1/p130Cas is functionally involved
in antiestrogen resistance, the full-length BCAR1/p130Cas
cDNA was introduced in antiestrogen-sensitive ZR-75-1 cells by
transfection. Five independent LXSN/BCAR1/p130Cas trans-
fectants were generated, carrying an intact transgene integrated
in the host genome as determined by Southern blot analysis.
Similarly, eight independent cell lines carrying the BCAR1/
p130Cas cDNA in an episomal vector were established. In ad-
dition, more than 22 vector-control cell lines have been raised.
All transfected cell lines were generated in estrogen-
containing medium and subsequently tested for proliferation in
the presence of either 4-hydroxy-tamoxifen or the pure anties-
trogen ICI 182,780. A typical example of such an assay with the
use of 4-hydroxy-tamoxifen is shown in Fig. 5, A. Aliquots of
the cultured cells have been used to measure the amount of
Bcar1/p130Cas protein with the use of western blotting and
immunodetection (Fig. 5, A). All cell lines exhibiting high ex-
pression of Bcar1/p130Cas (e.g., 4A12, B4, B6, and C4 and the
somatic cell hybrid D4E6) showed net proliferation in the pres-
ence of 4-hydroxy-tamoxifen. In contrast, ZR-75-1 and all vec-
tor control cell lines (e.g., C2, C6, D2, and D4) expressed very
low levels of or no Bcar1/p130Cas and failed to proliferate in the
presence of the antiestrogen. Similar results were obtained in the
assays by the use of the pure antiestrogen ICI 182,780 (data not
shown). Of interest, Bcar1/p130Cas-transfected cells underwent
a morphologic change when cultured in the presence of anties-
trogens (data not shown). The cells displayed a typical flattened
shape with multiple protrusions (similar to the virus-induced cell
lines), which may be suggestive of a reorganization of the cyto-
skeleton. Further experiments with the use of immunofluores-
cence are needed to verify these observations. To investigate the
possibility that Bcar1/p130Cas overexpression also generates re-
sistance to other drugs, we performed cell survival assays by use
of doxorubicin, 5-fluorouracil, and methotrexate. These pilot
experiments showed no relation between sensitivity to these
drugs and overexpression of Bcar1/p130Cas; i.e., comparable
ID50 (dose showing 50% inhibition) values were obtained for
overexpressing cell lines and cell lines without overexpression
(data not shown).
Northern blotting analysis of Bcar1/p130Cas-transfected cells
grown under antiestrogen selection revealed an impaired expres-
sion of the estrogen-regulated PS2 gene (43) similar to the pa-
rental cells (Fig. 5, B), suggesting that the proliferation of these
cells was independent of ER function. Because integrin and
growth factor-receptor pathways may signal through p130Cas to
the mitogen-activated protein kinase (MAPK) pathways (51–
54), we have performed preliminary experiments to monitor the
activation state of various MAPKs in BCAR1/p130Cas-
transfected cell lines. Specific antibodies directed against acti-
vated MAPKs (ERK, p38, and JNK) failed to document consti-
tutive activation of these kinases in the presence of antiestrogens
(not shown). Because of the slow growth and response kinetics
of the transfected cells in antiestrogen-supplemented cultures,
the levels of activated MAPK may have been below the thresh-
old of detection in our tests.
DISCUSSION
The mechanisms underlying antiestrogen resistance in breast
cancer are the subject of intensive study. Our working hypoth-
esis was based on the assumption that genetic or epigenetic
alterations in the tumor cells contribute to the failure of the
therapy. To identify target genes, we have employed a model
system of estrogen dependence resembling that seen in human
breast cancer. In this article, we describe the cloning and char-
acterization of the BCAR1 gene. On the basis of our findings,
BCAR1 appears to be the human homologue of the rat and
mouse p130Cas genes; their function is described below. Over-
expression of Bcar1/p130Cas in human estrogen-dependent ZR-
75-1 breast cancer cells is sufficient to drive cell proliferation in
the presence of antiestrogens. No difference in structure or size
of the BCAR1/p130Cas transcript was seen in the virus-infected
cell lines. This suggests that overexpression of the BCAR1/
p130Cas gene is achieved by increased activity of the BCAR1/
p130Cas gene promoter, likely due to the presence of strong
enhancer elements within the viral LTRs (55). This mechanism
of transcription enhancement is different from the observed viral
promoter-insertion activation of the BCAR3 gene that resulted
in an altered BCAR3 transcript and protein (43). It is possible
that such events are selected against, in the case of the BCAR1/
p130Cas gene, to ensure an intact and functional protein.
Our experiments indicate that BCAR1/p130Cas-mediated an-
tiestrogen resistance is not associated with resistance to other
drugs relevant to the treatment of breast cancer. In addition, the
ER does not play a crucial role in the resistant phenotype. Cell
lines obtained after viral integration in the BCAR1 locus (e.g.,
XI-13) completely lack ER expression and function (36) and
show comparable growth rates in the absence or presence of
antiestrogens (Fig. 1). The somatic cell hybrids containing the
BCAR1 locus and the BCAR1/p130Cas transfectants are estro-
gen responsive with respect to growth and regulation of PS2
expression. These variants exhibit antiestrogen-resistant cell
proliferation but are not dependent on antiestrogen for growth
(Fig. 1, B). These observations suggest a cell proliferation regu-
latory mechanism involving Bcar1/p130Cas, which bypasses the
ER-regulated pathway.
The observation that the BCAR1 gene is highly homologous
to the well-characterized rat and mouse p130Cas genes may help
to understand the mechanism of antiestrogen-resistant breast
cancer cell proliferation. Rat p130Cas has been identified as the
major tyrosine-phosphorylated protein in v-Src- and v-Crk-
transformed rat cells (46,56). Subsequent reports have impli-
cated p130Cas in various processes in different cell types, in-
cluding cell transformation (57,58), linking the extracellular
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matrix with the actin cytoskeleton (59,60), integrin signaling
(51,61–64), growth factor-receptor signaling (53,54,65–68), an-
tigen-receptor signaling (69), cell migration and invasion (70–
72), bacterial invasion (73,74), and essential cardiovascular de-
velopment (58). This varied role of p130Cas may be explained
by the presence of several protein–protein interaction domains
(46,75), which is the hallmark of this novel class of adapter
proteins. Family members are HEF1 (also designated CasL)
(76,77) and Efs (also termed Sin) (78,79), which may have dis-
tinct functions (80). The SH3 domain, in particular, is well con-
served between these family members and has been shown to
interact with proline-rich target sequences from FAK (49),
RAFTK (81), PTP-PEST (82), CAKbeta (83), and PTP1B (52).
The central part of p130Cas contains multiple potential tyro-
sine–phosphorylation sites capable of interacting with SH2 do-
main-containing proteins like Crk (84,85), Src (48), and Nck
(51). The C-terminal part of the p130Cas family members is well
conserved but has not yet been implicated in a particular func-
tion in mammalian cells. Together, the numerous documented
interactions and functions of p130Cas in various biologic pro-
cesses and in different cell types suggest a dynamic role for
p130Cas. The outcome of these complex interactions will de-
pend on the availability of binding partners (including their ac-
tivation status and affinity) and the specific process in that cell
type.
So far, little information is available regarding the role of
Bcar1/p130Cas in regulation of proliferation of breast epithelial
cells. The observation that expression of Bcar1/p130Cas in pri-
mary breast cancer predicted disease prognosis and response to
tamoxifen therapy (45) suggests a genuine role for Bcar1/
p130Cas in growth control of breast cancer cells. Further eluci-
dation of the pathway involved in Bcar1/p130Cas-mediated cell
proliferation in breast cancer cells may identify in vitro key
regulators and possibly novel clinical targets. The recognition
that both BCAR1/p130Cas and BCAR3 (42) can control prolif-
eration of breast cancer cells further supports the validity of our
model system to identify breast cancer antiestrogen resistant
genes.
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